Tokyo Tape
Sign in
← Koa Shoji Holdings

Quarterly report · Q2

9273.TEDINET S100Q755
Period2022-07-01 → 2022-12-31
Filed2023-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥11.2bn2022-07-01 → 2022-12-31Cons.Net sales
Revenue¥20.4bn2021-07-01 → 2022-06-30Cons.Net sales (5-year summary)
Revenue¥10.4bn2021-07-01 → 2021-12-31Cons.Net sales
Operating income¥2.2bn2022-07-01 → 2022-12-31Cons.Operating income
Operating income¥2.2bn2021-07-01 → 2021-12-31Cons.Operating income
Ordinary income¥2.2bn2022-07-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥3.8bn2021-07-01 → 2022-06-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.1bn2021-07-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥2.2bn2022-07-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥2.1bn2021-07-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥1.4bn2022-07-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.4bn2021-07-01 → 2022-06-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.4bn2021-07-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥1.4bn2022-07-01 → 2022-12-31Cons.Profit loss
Net income¥1.4bn2021-07-01 → 2021-12-31Cons.Profit loss
Total assets¥27.6bnat 2022-12-31Cons.Assets
Total assets¥26.2bnat 2022-06-30Cons.Assets
Total assets¥25.7bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥8.1bnat 2022-12-31Cons.Liabilities
Total liabilities¥7.6bnat 2022-06-30Cons.Liabilities
Net assets / equity¥19.6bnat 2022-12-31Cons.Net assets
Net assets / equity¥18.7bnat 2022-06-30Cons.Net assets
Net assets / equity¥17.7bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥8.9bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥9.1bnat 2022-06-30Cons.Cash and deposits
Cash & equivalents¥8.2bnat 2022-12-31Cons.Cash and cash equivalents
Cash & equivalents¥8.4bnat 2022-06-30Cons.Cash and cash equivalents
Cash & equivalents¥7.2bnat 2021-12-31Cons.Cash and cash equivalents
Cash & equivalents¥7.6bnat 2021-06-30dCons.Cash and cash equivalents
Operating cash flow¥518m2022-07-01 → 2022-12-31Cons.Net cash provided by used in operating activities
Operating cash flow¥2.1bn2021-07-01 → 2022-06-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥440m2021-07-01 → 2021-12-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥120m2022-07-01 → 2022-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥477m2021-07-01 → 2022-06-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥264m2021-07-01 → 2021-12-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥600m2022-07-01 → 2022-12-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥805m2021-07-01 → 2022-06-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥576m2021-07-01 → 2021-12-31Cons.Net cash provided by used in financing activities
EPS (basic)¥35.192022-07-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥19.92022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥59.552021-07-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥35.282021-07-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥19.982021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio70.8%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio71.1%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio68.9%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-12-31−¥925m
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-12-31−¥925m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-12-31¥22m
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2022-07-01 → 2022-12-31¥8.1bn
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2022-07-01 → 2022-12-31¥7.2bn
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2022-07-01 → 2022-12-31¥925m
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2022-07-01 → 2022-12-31¥1.4bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2022-07-01 → 2022-12-31¥4.0bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2022-07-01 → 2022-12-31¥4.0bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2022-07-01 → 2022-12-31¥761m
—segment totalrevenue2022-07-01 → 2022-12-31¥12.1bn
—segment totalrevenue external2022-07-01 → 2022-12-31¥11.2bn
—segment totalrevenue intersegment2022-07-01 → 2022-12-31¥925m
—segment totalsegment profit2022-07-01 → 2022-12-31¥2.1bn
Reconciling Itemsreconcilingrevenue2021-07-01 → 2021-12-31−¥964m
Reconciling Itemsreconcilingrevenue intersegment2021-07-01 → 2021-12-31−¥964m
Reconciling Itemsreconcilingsegment profit2021-07-01 → 2021-12-31¥19m
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2021-07-01 → 2021-12-31¥7.4bn
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2021-07-01 → 2021-12-31¥6.5bn
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2021-07-01 → 2021-12-31¥964m
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2021-07-01 → 2021-12-31¥1.3bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2021-07-01 → 2021-12-31¥3.9bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2021-07-01 → 2021-12-31¥3.9bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2021-07-01 → 2021-12-31¥862m
—segment totalrevenue2021-07-01 → 2021-12-31¥11.3bn
—segment totalrevenue external2021-07-01 → 2021-12-31¥10.4bn
—segment totalrevenue intersegment2021-07-01 → 2021-12-31¥964m
—segment totalsegment profit2021-07-01 → 2021-12-31¥2.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 499
ItemContextValueUnit
Electronically recorded obligations operating clPrior1YearInstant658864000JPY
Electronically recorded obligations operating clCurrentQuarterInstant822895000JPY
Short term loans payablePrior1YearInstant850000000JPY
Short term loans payableCurrentQuarterInstant850000000JPY
Current portion of long term loans payablePrior1YearInstant349904000JPY
Current portion of long term loans payableCurrentQuarterInstant373904000JPY
Income taxes payablePrior1YearInstant809405000JPY
Income taxes payableCurrentQuarterInstant794336000JPY
Provision for bonusesPrior1YearInstant48224000JPY
Provision for bonusesCurrentQuarterInstant35295000JPY
Other clPrior1YearInstant757440000JPY
Other clCurrentQuarterInstant705893000JPY
Current liabilitiesPrior1YearInstant4938004000JPY
Current liabilitiesCurrentQuarterInstant5603022000JPY
Long term loans payablePrior1YearInstant2291192000JPY
Long term loans payableCurrentQuarterInstant2116240000JPY
Deferred tax liabilitiesPrior1YearInstant6311000JPY
Deferred tax liabilitiesCurrentQuarterInstant1906000JPY
Provision for directors retirement benefitsPrior1YearInstant124588000JPY
Provision for directors retirement benefitsCurrentQuarterInstant130805000JPY
Net defined benefit liabilityPrior1YearInstant120339000JPY
Net defined benefit liabilityCurrentQuarterInstant125832000JPY
Other nclPrior1YearInstant103666000JPY
Other nclCurrentQuarterInstant90445000JPY
Noncurrent liabilitiesPrior1YearInstant2646098000JPY
Noncurrent liabilitiesCurrentQuarterInstant2465229000JPY
LiabilitiesPrior1YearInstant7584102000JPY
LiabilitiesCurrentQuarterInstant8068252000JPY
Capital stockPrior1YearInstant522277000JPY
Capital stockCurrentQuarterInstant522277000JPY
Capital surplusPrior1YearInstant205828000JPY
Capital surplusCurrentQuarterInstant205828000JPY
Retained earningsPrior1YearInstant17920673000JPY
Retained earningsCurrentQuarterInstant18879213000JPY
Treasury stockPrior1YearInstant-407000JPY
Treasury stockCurrentQuarterInstant-407000JPY
Shareholders equityPrior1YearInstant18648371000JPY
Shareholders equityCurrentQuarterInstant19606911000JPY
Valuation difference on available for sale securitiesPrior1YearInstant15990000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant16166000JPY
Deferred gains or losses on hedgesPrior1YearInstant1469000JPY
Deferred gains or losses on hedgesCurrentQuarterInstant-65179000JPY
Valuation and translation adjustmentsPrior1YearInstant17460000JPY
Valuation and translation adjustmentsCurrentQuarterInstant-49012000JPY
Net assetsPrior1YearInstant18665832000JPY
Net assetsCurrentQuarterInstant19557898000JPY
Liabilities and net assetsPrior1YearInstant26249934000JPY
Liabilities and net assetsCurrentQuarterInstant27626150000JPY
Net salesPrior1YTDDuration10355258000JPY
Net salesCurrentYTDDuration11166974000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-06-30pass
balance sheet identityconsolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2021-07-01/2021-12-31pass
statement vs summary · operating cash flowconsolidated 2022-07-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-07-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-07-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass